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Background
The term "Hodgkin's disease", now renamed as Hodgkin lymphoma, was first coined by Samuel Wilks, in recognition of the earlier report by Thomas Hodgkin from the Guy's hospital in London (Hodgkin, 1832) . The name Hodgkin's disease, popular for many years, reflected uncertainty regarding the cellular lineage of the Hodgkin/Reed-Sternberg (HRS) cells and questions regarding their reactive or neoplastic nature. Today we accept Hodgkin lymphoma as a neoplasm derived from B cells, in which the unique cellular microenvironment plays an important role in accurate diagnosis and pathobiology. The diagnosis of Hodgkin lymphoma in the modern era relies on an appropriate clinical setting, and morphological and immunophenotypic assessment. In addition, advances in therapy have led to a greater appreciation of the importance of the microenvironment, and the identification of new therapeutic targets. We now view Hodgkin lymphoma as more than a single disease. The unique features of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) have been recognized (Mason et al, 1994) . Moreover, nodular sclerosis classical Hodgkin lymphoma (NSCHL) exhibits major differences from mixed cellularity (MC) and lymphocyte depleted (LD) CHL, with the suggestion that they are separate entities as well. This review also will touch on diagnostic pitfalls, and conditions that mimic Hodgkin lymphoma.
Nodular lymphocyte predominant Hodgkin lymphoma

Clinical features
NLPHL is relatively uncommon (5-10% of all Hodgkin lymphomas) and shows unique clinicopathological features compared to CHL. It has a peak incidence in the 4th decade, but also affects children. There is a male preponderance of 3:1. Most patients present with low stage disease (Stage I or II) and have a good prognosis. The most common clinical presentation is long standing isolated lymphadenopathy without systemic symptoms. NLPHL affects peripheral lymph node groups with general sparing of the mediastinum and axial lymph nodes. Mesenteric lymph node involvement can be seen but is very rare. Conversely, advanced stage disease has an aggressive clinical course, with a poor response to traditional CHL regimens; newer data point towards the efficacy of treatment regimens used for aggressive B-cell non-Hodgkin lymphomas (Xing et al, 2014; Fanale et al, 2017) . The histological features and clinical presentation of advanced stage disease overlap with T-cell/ histiocyte-rich large B-cell lymphoma (THRLBCL), suggesting that they may represent a biological continuum (Hartmann et al, 2013a) .
Progressive transformation of germinal centres (PTGC) can occur in the same lymph node site as NLPHL, or may be found in uninvolved lymph nodes prior to a diagnosis of NLPHL, or following treatment (Ferry et al, 1992) . However, neither a definitive link between PTGC and NLPHL nor an elevated risk of progression to NLPHL has been identified.
Histology and immunophenotype
The neoplastic cells are termed lymphocyte predominant (LP) cells, replacing the older historical term of lymphocytic and histiocytic (L&H) cell, derived from the original Lukes and Butler category of lymphocytic and histiocytic predominant Hodgkin lymphoma. Due to the nuclear contour, these cells have also been referred to as "popcorn" cells. The infiltrate in NLPHL is generally vaguely nodular, but diffuse areas can be seen. (Fig 1) Six immunoarchitectural patterns of NLPHL were described (Fan et al, 2003) . In the initial stages, the background is rich in small B cells, related to an origin of the process within lymphoid follicles (Patterns A and B). The LP cells are distributed within nodules in close association with small B cells and the follicular dendritic cell (FDC) meshwork. The small B cells have the phenotype of mantle zone B cells. As the disease progresses, the LP cells extend beyond this follicular environment (Pattern C). Eventually, more T cells are recruited into the infiltrate and T cells become predominant. (Pattern D). Over time, the FDC meshworks and nodular architecture may be both lost with resultant diffuse architecture (Pattern E), resembling THRLBCL. Pattern F, which is rare, has a disorganized B-cell rich background. A mixture of 2 or more patterns is commonly observed in a single biopsy. The variant patterns (Patterns C-F) are more often associated with disease recurrence, with the recurrences often resembling THRLBCL (Hartmann et al, 2013b) .
The infiltrating T cells in NLPHL express a follicular T helper (TFH) cell phenotype, with positivity for CD4, PD1 (PDCD1) and CD57 (B3GAT1). The TFH cells are closely associated with LP cells with the formation of rosettes (Dorfman et al, 2006; Nam-Cha et al, 2008) . Rarely, cytological atypia in the background T cells can lead to suspicion for a peripheral T-cell lymphoma (Sohani et al, 2011) , and the non-neoplastic T cells may show co-expression of CD4 and CD8 by flow cytometry (Rahemtullah et al, 2006) , which may lead to misdiagnosis as an abnormal T cell process.
LP cells show expression of CD45 and pan B cell markers (Table I) . BCL6 is typically positive, which is characteristic of a germinal centre (GC) origin, although CD10, another GC marker, is negative (Anagnostopoulos et al, 2000) . Additionally, B cell transcription factors, PAX5, OCT1 (POU2F1) OCT2 (POU2F2), BOB.1 (POU2AF1) and PU.1 (SPI1) are positive, while often downregulated in CHL. The strong staining for OCT2 is especially useful in recognizing focal involvement. Immunoglobulin D (IgD) is expressed in the LP cells in some cases, which correlates with younger age group, male gender, cervical lymph node involvement and interfollicular distribution of LP cells (Prakash et al, 2006; Untanu et al, 2018) . IgD-positive NLPHL appears to be linked to prior infection by Moraxella catarrhalis, a common bacterium in the upper respiratory tract that expresses an IgD-binding protein, thus activating IgD-expressing B cells (Hartmann et al, 2015a) . CD30 (TNFRSF8) and CD15 (FUT4) are typically negative, although rare cases may express CD30, CD15 or both . However, CD30 + parafollicular immunoblasts are frequently present, which should not be misinterpreted as expression in the neoplastic cells and confused with CHL (Anagnostopoulos et al, 2000) . Only rare cases of NLPHL are positive for Epstein-Barr virus (EBV), a finding seen in both children and adults (Huppmann et al, 2014) .
Recent studies show that LP cells do not express the programmed cell death ligand 1 or 2 (PD-L1 [CD274] /PD-L2 [PDCD1LG2]) (Fromm et al, 2017) , in contrast to HRS cells in CHL which often express PD-L1.
Genetics and molecular biology
The immunoglobulin (Ig) genes are clonally rearranged in LP cells with evidence of somatic hypermutation, consistent with a GC origin (Kuppers et al, 1994; Marafioti et al, 1997) . The gene expression profile of microdissected LP cells points towards a late GC profile (Brune et al, 2008) . LP cells exhibit multiple chromosomal abnormalities, including rearrangements of BCL6 in about half of the cases (Franke et al, 2002; Rudiger et al, 2002; Wlodarska et al, 2004) .
Genomic studies have shown contradictory results regarding the relationship between NLPHL and THRLBCL. For example, earlier studies using comparative genomic hybridization (CGH) found a higher level of genomic imbalances in NLPHL than in THRLBCL, suggesting they are cytogenetically distinct (Franke et al, 2002) . However, more recent studies using array CGH showed similarities between NLPHL and THRLBCL, in support of a common molecular pathogenesis (Hartmann et al, 2015b) . Notably, a familial risk for NLPHL has been shown in several studies, and in some instances both NLPHL and THRLBCL occurred in the same family (Straus et al, 2001; Saarinen et al, 2011) .
Histological progression
A small percentage of NLPHL cases (3-14%) may progress to diffuse large B cell lymphoma (DLBCL) (Hansmann et al, 1989) . DLBCL may co-exist with NLPHL in a single site (Sundeen et al, 1988) , or occur later in the course of disease (Greiner et al, 1996; Huang et al, 2004) . Studies of both components indicate that they are clonally related (Greiner et al, 1996; Cotta et al, 2011; Hartmann et al, 2014) . In general, the clinical presentation of DLBCL following NLPHL is similar to that of de novo DLBCL with a risk of both nodal and extranodal disease (Huang et al, 2004) , while focal DLBCL co-existing with NLPHL may have less clinical impact (Sundeen et al, 1988) .
A more complex issue is the association of NLPHL with THRLBCL. On a practical basis, according to the guidelines of the revised World Health Organization classification, a focal area of NLPHL with diffuse areas resembling THRLBCL is designated as NLPHL with areas of Pattern E (Swerdlow et al, 2016) . A recurrence with a purely diffuse pattern consistent with THRLBCL is designated as "THRLBCL-like transformation of NLPHL", with indications that this progression is associated with an aggressive clinical course (Swerdlow et al, 2016) . Clinically, it is likely that advanced stage disease is the most crucial factor in therapeutic decision-making, irrespective of the exact histological pattern (Xing et al, 2014) . At this point a distinction between THRLBCL arising from NLPHL and de novo THRLBCL is still not possible .
Classical Hodgkin lymphoma
Classical Hodgkin lymphomas (CHL) account for approximately 85% of all Hodgkin lymphoma cases. In CHL the HRS cells usually show a repressed B-cell programme and defective immunoglobulin expression. CHL also differs from NLPHL in the character of the microenvironment. Based on histological features, four different subtypes have been designated, which include nodular sclerosis CHL (NSCHL), mixed cellularity CHL (MCCHL), lymphocyte-depleted CHL (LDCHL) and lymphocyte-rich CHL (LRCHL). In clinical practice, it is ideal to subclassify CHL as one of the four subtypes. However, a precise sub-classification is not always possible, especially when the biopsy material is limited. In those cases, the diagnosis of CHL, not further subclassified, may be made, but it remains important to distinguish cases of CHL from NLPHL.
Epidemiology
Epidemiological studies suggest that at least some of the subtypes of CHL represent different entities (Cartwright & Watkins, 2004; Mani & Jaffe, 2009) . NSCHL affects primarily young adults (ages 15-34 years) with a female predominance and is less common in the elderly. On the other hand, MCCHL and LDCHL exhibit a bimodal age distribution with one peak in the paediatric age group, and a second peak over 60 years. These differences also correlate with differences in socioeconomic status among the subtypes. NSCHL is associated with higher socioeconomic status (Clarke et al, 2005) , which has been postulated to be related to delayed exposure to common infections (Macmahon, 1957) . MCCHL and LDCHL are both more common in developing countries, and frequently associated with EBV infection. EBV is positive by immunohistochemical stains or in situ hybridization in HRS cells in 70-80% of MCCHL and LDCHL, but in only 10-25% of NSCHL (Gulley et al, 1994; Karube et al, 2013) . When present in HRS cells, the virus typically displays a latency type II pattern, with expression of EBNA1, LMP1 and LMP2A. A history of infectious mononucleosis carries a small but significant risk of subsequent MCCHL (Hjalgrim, et al 2003) .
NSCHL is the most common subtype of CHL in the Western world, followed by MCCHL. There are fewer epidemiological data regarding LRCHL, which tends to occur in an older patient population, and is relatively uncommon (5% of cases). Earlier epidemiological studies showed a sustained increase in the incidence of NSCHL in Europe over the period from 1978 to 1997, while the incidence of other subtypes remained steady (Clavel et al, 2006) . However, a recent study has also shown a decline in the incidence of NSCHL of 6% per year since 2007 (Glaser et al, 2015) .
Clinical features
Most patients with CHL present with lymphadenopathy. The commonly involved nodal sites include cervical, mediastinal, supraclavicular and axillary, with some variation in site preference among different subtypes. (Laurent et al, 2015) . Classical studies indicated that the spread of disease followed the physiological direction of lymphatic flow (Smithers et al, 1974) ; thus peripheral non-axial lymph node groups, such as mesenteric or epitrochlear lymph nodes, are rarely involved. Extranodal involvement usually arises from haematogenous dissemination, while primary extranodal disease is rare. The most commonly involved extranodal sites include lung, liver and bone (Musshoff, 1971) . Although sporadic studies, especially in the older literature, reported cutaneous involvement by CHL (Introcaso et al, 2008) , it is likely that these instances represent other entities, including EBV-positive mucocutaneous ulcer and primary cutaneous CD30-positive T-cell proliferative disease (lymphomatoid papulosis), both of which can resemble CHL (Dojcinov et al, 2010; Eberle et al, 2012) . If cutaneous involvement by CHL is seen, it is usually by direct extension.
There are also some subtype-specific clinical features. NSCHL usually presents with mediastinal mass, occurring in 80% of patients. MCCHL typically presents with peripheral lymphadenopathy, and mediastinal involvement is uncommon. LDCHL is often associated with an aggressive clinical course, with widespread involvement including bone marrow at diagnosis, and more common B symptoms (Klimm et al, 2011) . In contrast, LRCHL often presents with early-stage disease, with rare B symptoms; the clinical features are similar to those of NLPHL, although late relapses are rare (Diehl et al, 1999) .
Histological features
The initial diagnosis of CHL should be made on an adequate tissue biopsy. A fine needle aspiration or even a needle core biopsy is inadequate, as the assessment of architecture is important for an accurate diagnosis. Like NLPHL, CHL is characterized by a paucity of neoplastic cells and a rich inflammatory background. Whereas the features of HRS cells are comparable among the histological subtypes, the microenvironment shows substantial differences.
Nodular sclerosis classical Hodgkin lymphoma. In NSCHL cellular nodules are surrounded by partial or complete collagen bands, containing variable numbers of HRS cells, including lacunar variants, in a mixed inflammatory background. The HRS cells often form cellular aggregates that may be associated with necrosis and histiocytic reaction. NSCHL has traditionally been graded into NS1 and NS2, based on the histological criteria from the British National Lymphoma Investigation (BNLI) (MacLennan et al, 1989) . The highergrade NS2 lesions have more abundant HRS cells, frequent anaplastic-appearing HRS cells and areas of necrosis. In the original series NS2 was associated with poorer initial response to treatment and higher relapse rate (MacLennan et al, 1989) . However, the importance of grading is declining due to advances in therapy and is more relevant for cases with advanced clinical stage (van Spronsen et al, 1997) . Grading is currently not mandatory for clinical use.
Mixed cellularity and lymphocyte-depleted classical Hodgkin lymphoma. MCCHL and LDCHL share many clinical features and appear to represent part of a biological continuum. Both subtypes are often positive for EBV. They also both show association with human immunodeficiency virus infection (Biggar et al, 2006; Shiels et al, 2014) . MCCHL is characterized by classic HRS cells in a rich inflammatory background, including eosinophils, neutrophils, histiocytes and plasma cells. Although fine interstitial fibrosis is common, a thick capsule or broad bands of fibrosis are usually absent. The cellular composition of LDCHL is like that of MCCHL, but in general there is a greater abundance of histiocytes and fewer reactive lymphocytes.
Lymphocyte-rich classical Hodgkin lymphoma. LRCHL is the last subtype that was defined and distinguished from NLPHL (Diehl et al, 1999; Anagnostopoulos et al, 2000) . LRCHL bears some resemblance to NLPHL in that the background is also dominated by small B-lymphocytes that form nodules, often with regressed germinal centres in the periphery. Other inflammatory cells, such as eosinophils, are rare. Due to the histological resemblance, this subtype can easily be confused with NLPHL, and the demonstration of a classical HRS immunophenotype is essential in making the diagnosis. A minor subset has a more diffuse growth pattern.
Immunophenotype
Despite the variability in the histological appearance among the four subtypes, the malignant cells in CHL share a common phenotype, and immunohistochemical stains on paraffin sections are a useful tool. The most frequently used markers are CD30 and CD15. CD30 is expressed in nearly all cases, while CD15 is found in 75-85% of CHL cases. The strong expression of CD30 in HRS cells has led to the development of CD30-specific therapies, such as the antibody-drug conjugate Brentuximab Vedotin or reprogramed autologous T-cell therapies (Renner & Stenner, 2018) . IRF4/ MUM1 is positive in nearly all cases but is less useful in discriminating CHL from other mimics, such as anaplastic large cell lymphoma.
In contrast to NLPHL, which often retains a B-cell phenotype, the HRS cells typically show repression of the B-cell programme with loss of B-cell antigen expression and immunoglobulin production (Tzankov et al, 2003) . The pan B-cell marker CD20 was traditionally reported negative in most cases, although recent experience indicates more frequent positivity, probably due to improvement in antigen retrieval techniques. Even so, CD20 is generally variable in a given case within the neoplastic population. CD79a is less often positive. The only B-cell-restricted antigen that is nearly always expressed in CHL is PAX5, which is useful to establish the B-cell identity of the tumour cells. The nuclear expression of PAX5 is usually weaker than that seen in the background reactive B cells, which is another diagnostically useful feature. Notably, the HRS cells in LRCHL more frequently express B-cell transcription factors and CD20 than the other CHL subtypes (Nam-Cha et al, 2009).
T-cell markers, most commonly CD4 and CD2, are aberrantly expressed in the HRS cells in a small subset of NSCHL. Most T-cell antigen-positive cases are of the NS2 subtype and have a worse clinical outcome . The expression of cytotoxic molecules in HRS cells has also been linked to a poorer prognosis (Asano et al, 2006) .
The immunophenotype aids the diagnosis and is also useful to investigate potential therapeutic targets. For example, PD-L1 and/or PD-L2 are often overexpressed in HRS cells through different mechanisms, including gene amplification, EBV infection and JAK-STAT pathway activation (Fig 2A-B) . PD-L1/2 is thought to play an important role in shaping the immunosuppressive microenvironment in CHL through suppression of T-cell functions (Yamamoto et al, 2008; Carey et al, 2017) . Blockade of the PD-1 pathway has shown promising results in the treatment of relapsed or refractory CHL (Ansell et al, 2015; Younes et al, 2016) . A recent clinical trial also indicated a strong correlation between the intensity of PD-L1 staining and the response to PD-L1/PD-1 inhibitors (Chen et al, 2017) .
The profile of the tumour microenvironment has also been suggested to have prognostic impact in CHL. For instance, the number of tumour-associated macrophages (TAM) was strongly associated with refractoriness to therapy, early relapse and shortened survival in adult CHL patients (Steidl et al, 2010a; Tzankov et al, 2010; Deau et al, 2013; Touati et al, 2015) , although other studies have not confirmed the importance of TAMs (Gupta et al, 2013; Cencini et al, 2017) . Interestingly, PD-L1 is also highly expressed in Review ª Published 2018. This article is a U.S. Government work and is in the public domain in the USA TAMs (Fig 2C-D) , which physically colocalize with PD-L1-expressing HRS cells in the microenvironmental niche (Carey et al, 2017) . The expression of PD-L1 in TAMs may also contribute to an immunosuppressive environment, and the intensity of PD-L1 staining in TAMs correlates with clinical response to the PD-1 blockade (Chen et al, 2017) . The contribution of TAM-supplied PD-L1 probably explains some of the tumour-promoting effects attributed to TAMs in some studies. Additionally, a high degree of tumour-infiltrating mast cells has also been reported to correlate with poorer outcome in MCCHL (Andersen et al, 2016) , and was associated with fibrosis in NSCHL, probably related to the production of pro-fibrotic cytokines, such as IL13 and TGF-b (TGFB1) (Nakayama et al, 2016) . The composition of the reactive T cells may impact the prognosis in CHL. Patients with increased FOXP3-positive regulatory T cells were found to have a better outcome in some studies (Greaves et al, 2013) , while opposite results have been shown in others (Schreck et al, 2009) .
The usefulness of flow cytometry in the diagnosis of CHL is limited, as the HRS cells generally escape detection by this technique. Several studies identified changes in the phenotype of CHL-infiltrating T lymphocytes, including bright expression of CD7 and CD45 (PTPRC), and an elevated CD4:CD8 ratio (Fromm et al, 2010; Wu et al, 2016) . These features are not diagnostic, but the findings should prompt a more thorough histological investigation for CHL. Additionally, novel strategies have been recently developed in some laboratories to identify HRS cells by flow cytometry with high sensitivity and specificity, using a combination of antibodies reactive with antigens on HRS cells, including CD30, CD15, CD40, CD71 (TFRC) and CD95 (FAS) (Fromm & Wood, 2012) . However, these assays are currently not widely available in most clinical laboratories.
Molecular and cytogenetic studies
Molecular studies for B-cell clonality are generally not required to establish the diagnosis of CHL, as conventional polymerase chain reaction (PCR) analyses often give a false negative result, due to the scarcity of neoplastic cells. However, with single-cell isolation, clonal immunoglobulin gene rearrangement has been demonstrated (Kuppers et al, 1994) . The rearranged immunoglobulin genes harbour somatic hypermutations in the V regions, which supports the GC B cell derivation of HRS cells (Kanzler et al, 1996; Braeuninger et al, 1997) . Interestingly, although HRS and LP cells both contain rearranged immunoglobulin genes, unlike LP cells, HRS cells lack immunoglobulin expression at both mRNA and protein levels, which has been attributed to several possible reasons, including crippling mutations in the rearranged immunoglobulin gene or its promoter region (Kanzler et al, 1996; Theil et al, 2001) , downregulation of B cell transcription factors required for Ig expression, and hypermethylation in genes associated with the B-cell programmes. As damaging mutations in immunoglobulin genes and disruption of B-cell receptor signalling lead to apoptosis of normal GC cells, it was concluded that HRS cells are derived from pre-apoptotic GC B cells that are rescued from apoptosis by other transforming events (Kuppers, 2012) . Recent genetic studies have shown that HRS cells share a typical transcriptome pattern with a subset of GC cells that express CD30, suggesting their origin from these cells. Moreover, there is remarkable downregulation of genes involved in the regulation of genomic stability and cytokinesis in HRS cells, which may lead to their genomic instability and multinuclearity (Weniger et al, 2018) .
Cytogenetic and fluorescence in situ hybridisation studies show high prevalence of aneuploidy or hypertetraploidy, consistent with the multinucleation of HRS cells. Recent studies using array CGH to analyse copy number changes in microdissected HRS cells have consistently identified regions with recurrent gains or losses of chromosomal material, including gains in chromosomes 2p, 9p, 17q, 19q and 20q, and losses in 6q and 13q (Hartmann et al, 2008; Steidl et al, 2010b) . Several genes involved in important biological functions localize in those regions, including JAK2, CD274 (PDL1) and PDCD1LG2 (PDL2) (all at 9p24), and genes involved in nuclear factor (NF)-jB signalling, such as REL (2p16), RELB (19q13), CD40 (20q13) and MAP3K14 (17q21). The amplification at 9p24.1 is critical in leading to amplification of CD274/PDCD1LG2, specifically associated with both NSCHL and PMBL (Green et al, 2010) . In addition, amplification of JAK2 further induces PD-L1 protein expression.
Recent studies using next generation sequencing on microdissected CHL samples have further elucidated the genetic landscape of CHL. Recurrent mutations in the JAK-STAT pathway genes including STAT6, GNA13, XPO1 and ITPKB have been identified with high frequency . By identifying STAT6 mutation, the most frequently mutated gene in CHL, in the circulation, it has been shown that measuring circulating tumour DNA can be used to monitor residual disease in CHL (Spina et al, 2018) . Furthermore, transcriptome analysis on CHL-derived cell lines and/ or microdissected HRS cells have shown a gene expression profile distinct from NLPHL or other non-Hodgkin B-cell lymphomas, including down-regulation of B-cell receptor signalling and antibody responses, and upregulation of NF-jB and JAK-STAT signalling (Steidl et al, 2012; Tiacci et al, 2012) .
These genetic alterations and the consequential dysregulation probably play pivotal roles in the pathogenesis of CHL, and tremendous effort has been made to develop new therapies that target these key pathways (Mottok & Steidl, 2018) . For example, immune checkpoint inhibitors targeting the PD-L1/PD-1 axis, as described earlier, have proven effective in the treatment of CHL. JAK inhibitors, such as ruxolitinib, have also been actively tested in clinical trials (Van Den Neste et al, 2018) . Bortezomib, a proteasome inhibitor, has also been added to combination regimens for relapsed or refractory CHL with the aim to downregulate the NF-jB signalling pathways, although early results have not been successful (Mendler et al, 2008; Balzarotti et al, 2016) .
Differential diagnosis
Although most cases of CHL can be diagnosed based on morphological and immunophenotypic features, the distinction from other types of non-Hodgkin B-cell or T-cell lymphomas and a variety of EBV-associated lymphoproliferations can prove difficult. Here we discuss a few common conditions that are also common problems in a haematopathology consultation service.
B-cell lymphoma unclassifiable, with features intermediate between DLBCL and CHL (Grey zone lymphoma). As its name suggests, grey zone lymphoma (GZL) shows features of both large B-cell lymphoma and CHL or, more specifically, primary mediastinal large B-cell lymphomas (PMBL) and NSCHL. A close relationship between NSCHL and PMBL had been suspected for some years, as these tumours can present as composite lymphomas, or sequentially in the same patient. They also show similarities in their gene expression and genetic profiles (Rosenwald et al, 2003; Savage et al, 2003) . Thus, mediastinal GZL (MGZL) was proposed as a missing link, representing a tumour with transitional features (Traverse-Glehen et al, 2005) .
The tumour cells in MGZL resemble both PMBL (with a sheet-like growth pattern) and NSCHL (with pleomorphic large cells in a fibrotic stroma). Unlike CHL, there is usually a sparse inflammatory infiltrate and tumour cell density is consistently high (Fig 3) . There is often an asynchrony between morphology and immunophenotype. For example, the neoplastic cells may closely resemble HRS cells, but show a preserved B-cell programme, with strong and uniform expression of CD20 and CD79a. However, uniform expression of CD20 in a tumour that is otherwise typical for NSCHL should not lead to a diagnosis of MGZL. Conversely, MGZL may show a histological appearance suggestive of PMBL, but with strong CD30 or CD15 expression and loss of B-cell antigens (Traverse-Glehen et al, 2005) . Notably, genetic studies have identified chromosomal aberrations that are shared with both PMBL and NSCHL, with gains at 2p16 (REL locus) and 9p24.1 (loci of JAK2, CD274 and PDCD1LG2) (Eberle et al, 2011) . The gains at 9p24.1 are associated with expression of PD-L1, correlating with a response to checkpoint inhibitors in some patients with GZL (Melani et al, 2017) . The absence of EBV in nearly all cases helps in the differential diagnosis with EBV-positive DLBCL (see below).
Clinically, GZL presents most commonly in young male patients aged 20-40 years. Patients usually present with a bulky mediastinal mass, causing local symptoms. The disease can spread to supraclavicular lymph nodes, lung, liver, spleen and bone marrow, while involvement of other extranodal sites is rare (Eberle et al, 2011; Pilichowska et al, 2017) . Patients with GZL have a worse outcome compared with that of either CHL or PMBL (Wilson et al, 2014; Evens et al, 2015; Sarkozy et al, 2017) . Thus, the distinction of GZL from CHL or PMBL is important, as it has been recommended that these patients be treated with dose-intensive regimens (Wilson et al, 2014; Kritharis et al, 2016; Sarkozy et al, 2017) .
EBV-positive DLBCL, not otherwise specified. This disease was formerly designated as EBV-positive DLBCL of the elderly, but was later found to also sporadically occur in young patients (Nicolae et al, 2015) . A subset of cases shows overlapping histological features with CHL, with variable numbers of large transformed HRS-like cells and a polymorphic reactive component. The histological features may resemble those of THRLBCL, but the presence of EBV helps in confirming the diagnosis (Lim et al, 2002) . Clinically, both nodal and extranodal sites can be involved, although the disease is predominantly nodal in young patients. The most commonly involved extranodal sites are the lungs and gastrointestinal tract. The prognosis also differs significantly between older and young patients, in that it is highly aggressive in elderly patients, with a median survival of about 2 years, much worse than CHL or EBV-negative DLBCL (Asano et al, 2009) . Younger patients appear to have an excellent prognosis (Nicolae et al, 2015) .
Immunophenotypically, the neoplastic cells have a preserved B-cell programme, and often show an activated B-cell phenotype with expression of IRF4/MUM1. CD30 is frequently positive, while CD15 is sometimes co-expressed. EBV-positive atypical cells can be demonstrated by in situ hybridization of EBV-encoded RNAs (EBER), and the EBVinfected cells usually exhibit type II or type III EBV latency, expressing LMP1 with or without EBNA2. The association with EBV is believed to be secondary to age-related immunosenescence. However, even in younger patients, a tolerogenic immune environment characterized by high expression of PD-L1 and IDO (IDO1) in tumour cells and/ or the histiocytic/dendritic cell microenvironment can often be found (Nicolae et al, 2015) .
EBV-associated B-cell lymphoproliferations. A variety of other EBV-associated B-cell lymphoproliferations of varied malignant potential may mimic CHL, and include EBV-positive mucocutaneous ulcer and polymorphic B-cell lymphoproliferative disorders (B-LPD) (Dojcinov et al, 2011; Natkunam et al, 2017) . EBV-positive mucocutaneous ulcer is a newly recognized EBV-associated B-cell proliferation, often with Hodgkin-like features, occurring in patients with age-related or iatrogenic immunosuppression (Dojcinov et al, 2010) . It is characterized by localized involvement in cutaneous or mucosal sites and an indolent clinical course, generally with good response to conservative management. Patients usually present with sharply circumscribed, often painful, ulcerative lesions in the oral mucosa, skin or gastrointestinal tract. The presence of lymph node involvement should suggest an alternative diagnosis. Histologically, there is usually a dense polymorphic infiltrate in the ulcer base, consisting of a variable number of plasma cells, eosinophils, histiocytes and large transformed cells resembling HRS cells (Fig 4) . At the base of the lesion there is a band-like infiltrate of mature T cells, contributing to the sharp demarcation of the process from the underlying soft tissue. The large transformed cells are B cells with variable expression of CD20 and strong CD30; CD15 is expressed in about half of the cases. Both EBER and LMP1 are expressed. In immunocompetent elderly individuals, spontaneous regression may be seen. For most patients receiving therapeutic immunosuppression, the lesions usually respond to reduction in immunosuppression, with rituximab used in some cases (Hart et al, 2014) . Spread beyond the local site is rare, and the presence of nodal involvement should suggest another EBV-related lesion.
Polymorphic B-LPDs are morphologically mass-forming lesions that contain atypical B cells, including some that may resemble HRS cells. In the post-transplant setting, they are designated as polymorphic post-transplant lymphoproliferative disorders (PTLD), but polymorphic PTLD-like lesions can be seen in other, mainly iatrogenic, immunodeficiency settings (Natkunam et al, 2018) . They may present in nodal or extranodal sites. Most polymorphic B-LPDs contain a mixed infiltrate of B cells with a full range of maturation from small and medium-sized B cells to immunoblasts and mature plasma cells. A subset of cases may contain HRS-like cells, but in contrast to CHL, EBER is positive in the full morphological spectrum, and not confined to the HRS-like cells. The distinction of polymorphic PTLD with HRS-like cells from true CHL-type PTLD (considered a form of monomorphic PTLD) is important, as the clinical management will differ (Dierickx et al, 2015) . Cases of polymorphic B-LPD occurring in patients receiving long term therapy with methotrexate provide a particular diagnostic challenge and may closely mimic CHL (Kamel et al, 1996) . In this setting a complete clinical history is essential, as withdrawal of immunosuppressive therapy will often lead to clinical regression (Natkunam et al, 2017) .
Anaplastic large cell lymphoma. Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma characterized by strong CD30 expression. It may or may not be associated with ALK rearrangement. Clinically, most patients present with advanced stage, with peripheral or abdominal lymphadenopathy, often associated with involvement of extranodal tissue (less common in ALK-negative cases) and bone marrow. Some patients may have a leukaemic presentation.
Histologically, ALCL shows a broad morphological spectrum, but the neoplastic cells typically show horseshoeshaped nuclei ("hallmark" cells). The neoplastic cells may range from small to very large, and only rarely should be confused with HRS cells. The tumour cells often grow in cohesive sheets, which may mimic the syncytial variant of NSCHL (Vassallo et al, 2006) . Involvement of lymph node sinuses is another typical feature of ALCL, and is rarely seen in CHL. Immunophenotypically, CD30 is strongly positive, except in the small cell variant, while the expression of CD15 is rare. The majority of ALCLs express one or more T-cell antigens (CD2, CD5 or CD4, while CD3 is often negative), whereas a subset may show a so-called null-cell phenotype, with loss of all T-cell markers. In general, the expression of B-cell markers, such as PAX5, or less commonly CD20, and CD15 suggest the diagnosis of CHL. A panel of immunohistochemical stains including EMA, CD45 and cytotoxic molecules may also aid in the differential diagnosis. In difficult cases, proof of T-cell clonality by PCR may help to rule out CHL, while finding clonal immunoglobulin gene rearrangement favours Hodgkin lymphoma.
Peripheral T-cell lymphomas with "Hodgkin-like" cells. Peripheral T-cell lymphomas (PTCLs) encompass a functionally and morphologically diverse group of lymphomas. A subset of PTCLs, especially those with a follicular helper T-cell phenotype such as angioimmunoblastic T-cell lymphoma, may contain HRS-like cells of B-cell lineage that are EBV-positive (Moroch et al, 2012; Nicolae et al, 2013; Eladl et al, 2017) (Fig 5) . The HRS-like cells are positive for PAX5 or CD20, and often express both CD30 and CD15. As atypia in the background T-cell population may be minimal, misdiagnosis as CHL may occur. In rare cases of PTCL the neoplastic cells themselves may express both CD30 and CD15, mimicking HRS cells and suggesting a diagnosis of CHL (Barry et al, 2003) . In most cases, tumour cell density is high and the neoplastic cells are often cohesive, resembling ALCL. HRS-like cells with expression of both CD30 and CD15 have also been reported in primary cutaneous CD30-positive T-cell LPDs, and in instances of lymph node involvement can provide a diagnostic challenge to the unwary (Eberle et al, 2012) .
Conclusion
A variety of benign and malignant lymphoid proliferations can display histological features resembling Hodgkin lymphoma. All of these Hodgkin mimics emphasize the importance of a complete clinical history and an adequate excisional biopsy for proper diagnosis. In challenging cases expert consultation should be sought, and appropriate immunophenotypic and molecular studies may be required for resolution of the diagnosis. Communication between the treating physician and the pathologist is critical, both in terms of establishing an initial diagnosis, but also for patient management. With the continued expansion and availability of targeted agents, detailed pathological characterization of the neoplastic cells and their microenvironment will be paramount.
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